Regeneus initiates cancer vaccine trial

Company News

Regeneus (ASX:RGS) has announced the commencement of a trial of its cancer vaccine technology Kvax, in combination with chemotherapy as a treatment of canine lymphoma. 
Veterinary Oncologists at the Small Animal Specialist Hospital in Sydney will conduct the trial.
The trial will use Kvax together with chemotherapy to seek to extend remission times for 45 dogs with lymphoma.
Once in remission, the dog may then be treated with Kvax. 
Lymphoma is the most commonly treated cancer in dogs.
Regeneus reported a loss of $6.6 million at 30 June 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.